Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prime Medicine Inc (NQ: PRME )

4.195 -0.195 (-4.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 700,383
Open 4.330
Bid (Size) 4.200 (5)
Ask (Size) 4.390 (50)
Prev. Close 4.390
Today's Range 4.130 - 4.480
52wk Range 4.110 - 13.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PRME Stock Earnings: Prime Medicine Misses EPS for Q2 2024
PRME stock results show that Prime Medicine missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire

Performance

YTD
-52.11%
-52.11%
1 Month
-24.41%
-24.41%
3 Month
-25.22%
-25.22%
6 Month
-37.76%
-37.76%
1 Year
-65.42%
-65.42%

More News

Read More
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
Via InvestorPlace
Exposures Product Safety
Recap: Prime Medicine Q4 Earnings
Via Benzinga
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
Via The Motley Fool
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
Via InvestorPlace
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
Via InvestorPlace
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Prime Medicine, Inc.
Via GlobeNewswire
PRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024
Via InvestorPlace
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
From Prime Medicine, Inc.
Via GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
From Prime Medicine, Inc.
Via GlobeNewswire
2 Magnificent Growth Stocks With Room to Run
Via The Motley Fool
Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging
Via InvestorPlace
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
Via InvestorPlace
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.